Premium
Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation
Author(s) -
Shinoda Masahiro,
Ebinuma Hirotoshi,
Itano Osamu,
Yamagishi Yoshiyuki,
Obara Hideaki,
Kitago Minoru,
Nakamoto Nobuhiro,
Hibi Taizo,
Yagi Hiroshi,
Abe Yuta,
Matsubara Kentaro,
Chu Posung,
Wakayama Yuko,
Taniki Nobuhito,
Yamaguchi Akihiro,
Amemiya Ryusuke,
Miyake Rei,
Mizota Takamasa,
Kanai Takanori,
Kitagawa Yuko
Publication year - 2016
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12666
Subject(s) - medicine , simeprevir , ribavirin , pegylated interferon , tolerability , hepatitis c , gastroenterology , adverse effect , calcineurin , liver transplantation , transplantation , hepatitis c virus , surgery , immunology , virus
Aim Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after living donor liver transplantation (LDLT) have not been well reported. In this study, we assessed the outcomes of patients with recurrent hepatitis C (genotype 1) after LDLT who received triple therapy at our hospital. Methods SMV/PEG IFN/RBV was administrated for 12 weeks (triple therapy), followed by another 12 weeks or extended period of PEG IFN/RBV (dual therapy). Virological response, interaction with calcineurin inhibitors and adverse events were retrospectively analyzed. Results Ten patients with recurrent hepatitis C after LDLT completed 12 weeks of triple therapy. Nine patients achieved rapid or early virological response, and one patient was a non‐responder. The nine responders received subsequent dual therapy, and the duration of dual therapy was extended (24 to 36 weeks) in five cases. Although one patient was in relapse 8 weeks after completing the standard duration (12 weeks) of dual therapy, eight patients achieved sustained virological response for 12 weeks (SVR12). The SVR12 rate was 80%. Trough levels of calcineurin inhibitor did not show marked changes after introduction of SMV in all cases. There were no major adverse events associated with SMV. Conclusion SMV treatment may be a safe and effective option for recurrent hepatitis C after LDLT.